Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration
Exscientia plc (Nasdaq: EXAI) announced the advancement of two additional discovery programmes within its collaboration with Sanofi. The company will receive $15 million in milestone payments for these achievements. Both lead compounds have met the product profile requirements to transition to the lead optimisation phase and have shown high differentiation potential for best-in-class assets.
Exscientia is eligible for over $600 million in additional milestone payments for these two programmes, as well as high-single-digit to mid-teen royalties on product sales. Three programmes in the partnership have now advanced through initial milestones, with multiple more progressing at earlier stages. The milestone payment is expected to be received in Q4 2024 and will be recognised as revenue over the collaboration duration.
Exscientia plc (Nasdaq: EXAI) ha annunciato l'avanzamento di due ulteriori programmi di scoperta all'interno della sua collaborazione con Sanofi. L'azienda riceverà 15 milioni di dollari in pagamenti di traguardo per questi risultati. Entrambi i composti principali hanno soddisfatto i requisiti del profilo di prodotto per passare alla fase di ottimizzazione e hanno dimostrato un alto potenziale di differenziazione per diventare asset di punta.
Exscientia è idonea a ricevere oltre 600 milioni di dollari in ulteriori pagamenti di traguardo per questi due programmi, oltre a royalties a cifra singola alta fino a quelle a due cifre sulle vendite di prodotto. Tre programmi nella partnership hanno ora superato i traguardi iniziali, mentre molti altri stanno progredendo in fasi precedenti. Si prevede che il pagamento di traguardo venga ricevuto nel quarto trimestre del 2024 e sarà riconosciuto come ricavo durante la durata della collaborazione.
Exscientia plc (Nasdaq: EXAI) anunció el avance de dos programas adicionales de descubrimiento en colaboración con Sanofi. La empresa recibirá 15 millones de dólares en pagos por hitos por estos logros. Ambos compuestos principales han cumplido con los requisitos del perfil del producto para pasar a la fase de optimización y han mostrado un alto potencial de diferenciación para activos de primera clase.
Exscientia es elegible para más de 600 millones de dólares en pagos adicionales por hitos para estos dos programas, así como regalías de un solo dígito alto a dígitos medianos sobre las ventas del producto. Tres programas en la asociación han avanzado a través de hitos iniciales, con múltiples más progresando en etapas anteriores. Se espera que el pago por hitos se reciba en el cuarto trimestre de 2024 y se reconocerá como ingreso durante la duración de la colaboración.
Exscientia plc (Nasdaq: EXAI)는 Sanofi와의 협력에서 두 개의 추가 발견 프로그램의 진전을 발표했습니다. 이 회사는 이러한 성과에 대해 1,500만 달러의 이정표 지급을 받을 예정입니다. 두 주요 화합물 모두 최적화 단계로 전환할 수 있는 제품 프로필 요구 사항을 충족하였으며, 최고 등급 자산에 대한 높은 차별화 잠재력을 보여주었습니다.
Exscientia는 이 두 프로그램에 대해 6억 달러 이상의 추가 이정표 지급을 받을 수 있습니다, 또한 제품 판매에 대한 높은 한 자리 수에서 중간 두 자리 수의 로열티를 받을 수 있습니다. 현재 파트너십 내의 세 개 프로그램이 초기 이정표를 넘었으며, 더 많은 프로그램이 초기 단계에서 진행되고 있습니다. 이정표 지급은 2024년 4분기에 수령될 예정이며, 협력 기간 동안 수익으로 인식될 것입니다.
Exscientia plc (Nasdaq: EXAI) a annoncé l'avancement de deux programmes de découverte supplémentaires dans le cadre de sa collaboration avec Sanofi. L'entreprise recevra 15 millions de dollars en paiements de jalons pour ces réalisations. Les deux composés principaux ont satisfait aux exigences de profil de produit pour passer à la phase d'optimisation et ont démontré un fort potentiel de différenciation pour des actifs de premier ordre.
Exscientia est éligible à plus de 600 millions de dollars de paiements de jalons supplémentaires pour ces deux programmes, ainsi qu'à des royalties de haut niveau à un chiffre jusqu'à des niveaux moyens à deux chiffres sur les ventes de produits. Trois programmes dans le partenariat ont maintenant avancé à travers des jalons initiaux, plusieurs autres progressant à des phases antérieures. Le paiement de jalon est prévu pour le quatrième trimestre de 2024 et sera reconnu comme revenu pendant la durée de la collaboration.
Exscientia plc (Nasdaq: EXAI) hat den Fortschritt von zwei zusätzlichen Entdeckungsprogrammen im Rahmen ihrer Zusammenarbeit mit Sanofi bekannt gegeben. Das Unternehmen erhält 15 Millionen Dollar an Meilensteinzahlungen für diese Erfolge. Beide Hauptverbindungen haben die Produktprofilanforderungen erfüllt, um in die Phase der Leitoptimierung überzugehen, und haben ein großes Differenzierungspotenzial für erstklassige Vermögenswerte gezeigt.
Exscientia hat Anspruch auf über 600 Millionen Dollar an zusätzlichen Meilensteinzahlungen für diese beiden Programme sowie auf hohe einstellige bis mittlere zweistellige Royalties auf den Produktverkauf. Drei Programme in der Partnerschaft haben nun die ersten Meilensteine erreicht, während mehrere weitere in früheren Phasen vorankommen. Die Meilensteinzahlung wird voraussichtlich im vierten Quartal 2024 eingehen und über die Dauer der Zusammenarbeit als Umsatz anerkannt werden.
- Received $15 million in milestone payments from Sanofi collaboration
- Two discovery programmes advanced to lead optimisation phase
- Potential for over $600 million in additional milestone payments
- Eligible for high-single-digit to mid-teen royalties on product sales
- Three programmes in the partnership have advanced through initial milestones
- None.
Insights
This news is significantly positive for Exscientia, demonstrating tangible progress in its collaboration with Sanofi. The achievement of milestones for two programmes validates Exscientia's AI-driven drug discovery platform and its ability to design potentially best-in-class molecules. The immediate financial impact includes a
More importantly, the long-term potential is substantial. Exscientia is eligible for over
With three programmes now advanced through initial milestones and multiple others progressing, the Sanofi collaboration appears to be a key value driver for Exscientia. This news should bolster investor confidence in the company's business model and its ability to monetize its AI platform through strategic partnerships.
The advancement of these two programmes underscores Exscientia's capabilities in AI-driven drug discovery. The company's ability to design highly differentiated molecules that meet stringent product profile requirements is a strong indicator of its technological edge in the competitive biotech landscape.
The transition to lead optimisation phase is a critical step in drug development, suggesting these compounds have shown promising results in early-stage research. The potential for best-in-class assets is particularly noteworthy, as it could lead to significant market opportunities if the drugs eventually reach commercialization.
While specific therapeutic areas aren't mentioned, the collaboration's progress across multiple programmes demonstrates the versatility of Exscientia's platform. This broad applicability could attract further partnerships and expand the company's pipeline, potentially de-risking its overall portfolio and enhancing long-term value prospects.
Both programmes demonstrate Exscientia’s ability to design highly differentiated, potentially best-in-class molecules
Exscientia will receive
Three programmes in the partnership have now advanced through initial milestones with multiple more progressing at earlier stages
“We are excited to announce the advancement of these programmes. This is testament to our consistent ability to design compounds that solve complex problems,” said David Hallett, Ph.D., interim Chief Executive Officer and Chief Scientific Officer of Exscientia. “We look forward to continuing to work with Sanofi to advance these programmes towards development, and ultimately working together to bring potential new treatment options to patients with significant unmet need.”
Exscientia will receive
About Exscientia
Exscientia is a technology-driven drug design and development company, committed to creating more effective medicines for patients, faster. Exscientia combines precision design with integrated experimentation, aiming to invent and develop the best possible drugs in the most efficient manner. Operating at the interfaces of human ingenuity, artificial intelligence (AI), automation and physical engineering, we pioneered the use of AI in drug discovery as the first company to progress AI-designed small molecules into a clinical setting. We have developed an internal pipeline focused on oncology, while our partnered pipeline extends to many other therapeutic areas. By leading this new approach to drug creation, we believe we can change the underlying economics of drug discovery and rapidly advance the best scientific ideas into medicines for patients.
For more information visit us on www.exscientia.com or follow us on LinkedIn @ex-scientia and X @exscientiaAI.
Forward-looking Statements
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” and “projects” or similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, statements regarding the further development of the two programmes under the collaboration with Sanofi, including advancing the product candidates through optimisation phrase and into the clinic; the creation of best-in-class therapies which meet unmet medical needs in inflammation and oncology; expectations and benefits related to the Sanofi collaboration including the development of additional molecule programmes and potential for future milestone payments; and the ability of Exscientia’s technology to design compounds to create more effective medicines for patients. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to: the initiation, scope and progress of Exscientia’s and its partners’ planned and ongoing preclinical studies and clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; the development and deployment of new technology and facilities; the process of discovering, developing and commercialising product candidates that are safe and effective for use as human therapeutics and the endeavour of building a business around such product candidates; and the process of creating a combined company with Recursion Pharmaceuticals and subsequent activities by any such combined company. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Exscientia’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 21, 2024, and other filings that Exscientia makes with the SEC from time to time (which are available at https://www.sec.gov/), the events and circumstances discussed in such forward-looking statements may not occur, and Exscientia’s actual results could differ materially and adversely from those anticipated or implied thereby. Although Exscientia’s forward-looking statements reflect the good faith judgement of its management, these statements are based only on facts and factors currently known by the Company. As a result, investors are cautioned not to rely on these forward-looking statements. Exscientia undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241016255653/en/
Investor Relations:
Sara Sherman
investors@exscientia.ai
Media:
David Keown
media@exscientia.ai
Source: Exscientia plc
FAQ
What milestone payments did Exscientia (EXAI) receive from Sanofi?
How many Exscientia (EXAI) programmes have advanced in the Sanofi partnership?
What additional payments is Exscientia (EXAI) eligible for in the Sanofi collaboration?
When will Exscientia (EXAI) receive the $15 million milestone payment?
